[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531040":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":50,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"Patients with pulmonary embolism and using direct oral anticoagulants",null,[12],"Drug: Direct oral anticoagulant",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Direct oral anticoagulant","Patients take DOACs according to their condition, with the dosage determined by the clinical physician.",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"juhong Shi, M.D","CONTACT","+8513701178492","shijh@pumch.cn",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"min Peng, M.D","+8618510797366","pengmin@pumch.cn",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Beijing","Beijing Municipality","100730","China","CN",{"type":38,"coordinates":39},"Point",[40,41],116.39723,39.9075,{"lat":41,"lon":40},[44,47],{"name":45,"role":22,"phone":46,"phoneExt":10,"email":24},"Juhong Shi, M.D","+8613701178492",{"name":48,"role":22,"phone":49,"phoneExt":10,"email":28},"Min Peng, M.D","+8613581888792",{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100531040","rivaroxaban-in-elderly-chinese-venous-thromboembolism-patients-100531040",false,"NCT06194617","Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients","The Exploratory Study on Clinical Rational Use of Rivaroxaban Dosing in Elderly Chinese Population","Inclusion Criteria:\n\n* (1) Adult patients with objectively diagnosed acute symptomatic pulmonary embolism (with or without concurrent deep vein thrombosis) by imaging, who have completed acute anticoagulation and entered the anticoagulation maintenance phase; (2) Life expectancy greater than 3 months; (3) Meeting the indications for Xa factor inhibitor use; (4) Willingness to participate in this study, sign the informed consent form, and adhere to regular follow-ups.\n\nExclusion Criteria:\n\n* (1) Moderate or severe hepatic impairment (Child-Pugh Class B or C); (2) Severe renal impairment (CrCl \\\u003C 15ml\u002Fmin); (3) Pregnant or breastfeeding women; (4) Spontaneous bleeding tendencies, such as coagulation disorders or low platelet count (PLT \\\u003C 20×10\\^9\u002FL); (5) Contraindications to other Xa factor inhibitors' usage; (6) Patients diagnosed with hereditary thrombophilia and antiphospholipid syndrome.",true,"ALL","18 Years",{"count":63,"type":64},300,"ESTIMATED","OBSERVATIONAL","There's no unified recommendation in clinical practice regarding adjusting dosages for different patient types, especially when adverse events occur. While rivaroxaban typically doesn't require coagulation monitoring, in elderly patients, particularly those with multiple medications, finding appropriate lab indicators becomes crucial to gauge its anticoagulant effect. This aids in evaluating precise rivaroxaban dosing for the elderly, balancing bleeding risks and recurrence. Clinical pharmacological studies suggest that drug pharmacokinetics and pharmacodynamics in different populations can guide dosage optimization. Hence, this study aims to provide a basis for optimizing dosing regimens in high-risk elderly patients in China by exploring pharmacokinetic and pharmacodynamic indicators in clinical practice.",[68,69,70],"Pulmonary Embolism","Venous Thromboembolism","Anticoagulant-induced Bleeding",[68,69,72],"Direct Oral Anticoagulants","2023-12-22",{"date":75,"type":76},"2024-01-08","ACTUAL",{"date":78,"type":76},"2021-04-01",{"date":80,"type":64},"2026-09-30",{"name":5,"class":6},1]